283 related articles for article (PubMed ID: 14656408)
1. Novel PDE5 inhibitors for the treatment of male erectile dysfunction.
Kalsi JS; Bahadur G; Muneer A; Ozturk O; Christopher N; Ralph DJ; Minhas S
Reprod Biomed Online; 2003; 7(4):456-61. PubMed ID: 14656408
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications.
Agarwal P; Sander GE; Giles TD
Am J Geriatr Cardiol; 2004; 13(6):332-5. PubMed ID: 15538074
[No Abstract] [Full Text] [Related]
3. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
Briganti A; Salonia A; Deho' F; Zanni G; Barbieri L; Rigatti P; Montorsi F
World J Urol; 2005 Dec; 23(6):374-84. PubMed ID: 16273417
[TBL] [Abstract][Full Text] [Related]
4. New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.
Mason RG
J R Soc Promot Health; 2003 Jun; 123(2):79-80. PubMed ID: 12852189
[No Abstract] [Full Text] [Related]
5. Phosphodiesterase-5 inhibitors and their hemodynamic effects.
Prisant LM
Curr Hypertens Rep; 2006 Aug; 8(4):345-51. PubMed ID: 16884667
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 5 inhibitors in male sexual dysfunction.
Kuthe A
Curr Opin Urol; 2003 Sep; 13(5):405-10. PubMed ID: 12917517
[TBL] [Abstract][Full Text] [Related]
7. Overview of phosphodiesterase 5 inhibition in erectile dysfunction.
Rosen RC; Kostis JB
Am J Cardiol; 2003 Nov; 92(9A):9M-18M. PubMed ID: 14609619
[TBL] [Abstract][Full Text] [Related]
8. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference.
Ströberg P; Murphy A; Costigan T
Clin Ther; 2003 Nov; 25(11):2724-37. PubMed ID: 14693300
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction.
Dunn ME; Althof SE; Perelman MA
Int J Impot Res; 2007; 19(2):119-23. PubMed ID: 16738695
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies.
McCullough A
Curr Urol Rep; 2004 Dec; 5(6):451-9. PubMed ID: 15541215
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
[TBL] [Abstract][Full Text] [Related]
12. [Erectile dysfunction (ED) and diabetes mellitus].
Takahashi Y
Nihon Rinsho; 2005 Jun; 63 Suppl 6():553-7. PubMed ID: 15999768
[No Abstract] [Full Text] [Related]
13. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
Vickers MA; Satyanarayana R
Int J Impot Res; 2002 Dec; 14(6):466-71. PubMed ID: 12494279
[TBL] [Abstract][Full Text] [Related]
14. Editorial comment on the manuscript entitled 'Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction'.
Perimenis P
Expert Opin Pharmacother; 2005 Jan; 6(1):1-2. PubMed ID: 15709877
[No Abstract] [Full Text] [Related]
15. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus.
Vardi M; Nini A
Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD002187. PubMed ID: 17253475
[TBL] [Abstract][Full Text] [Related]
16. New phosphodiesterase inhibitors in the treatment of erectile dysfunction.
Anderson PC; Gommersall L; Hayne D; Arya M; Patel HR
Expert Opin Pharmacother; 2004 Nov; 5(11):2241-9. PubMed ID: 15500370
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate.
Broderick GA; Donatucci CF; Hatzichristou D; Torres LO; Valiquette L; Zhao Y; Loughney K; Sides GD; Ahuja S
J Sex Med; 2006 Jul; 3(4):668-675. PubMed ID: 16839323
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase 5 inhibitors for erectile dysfunction.
Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
[TBL] [Abstract][Full Text] [Related]
19. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.
Shabsigh R; Seftel AD; Rosen RC; Porst H; Ahuja S; Deeley MC; Garcia CS; Giuliano F
Urology; 2006 Oct; 68(4):689-96. PubMed ID: 17070333
[No Abstract] [Full Text] [Related]
20. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
